# Alnylam (ALNY) Q3 2026 earnings

Results filed 2026-10-29 for the quarter ended 2026-09-30. Source page: https://earnings.opennash.com/companies/alny/2026-q3/
Press release and documents: https://www.sec.gov/Archives/edgar/data/1178670/000117867026000074/0001178670-26-000074-index.htm
> Summaries and transcripts are machine-generated and can contain errors.

## In brief

Alnylam enlarged its TRITON-CM nucresiran trial to about 2,250 patients, keeping a 2030 ATTR-CM launch, while AMVUTTRA's cardiomyopathy launch kept driving TTR growth.

AMVUTTRA's ATTR-CM launch remained the main driver of demand. U.S. prescriptions grew about 70% year over year, and more than 2,000 new prescribers have been added since March 2025. Abroad, ATTR-CM launches in Japan, Germany and Italy added to growth. New HELIOS-B analyses showed consistent benefit with or without baseline tafamidis. Brezosiran, for Huntington's disease, showed a 60-64% mean reduction of mutant huntingtin in spinal fluid.
Management wants durable TTR leadership through nucresiran, plus a second growth platform beyond TTR through brezosiran, mivelsiran and other RNAi programs. The tension is access. A proposed CMS change to 340B reimbursement could take effect January 1, 2027, and Alnylam is relying on contracting and alternative care sites to protect access. TRITON-CM's larger size also adds execution risk for the 2030 launch.

## Key numbers

| Metric | Value | Change | Basis |
| --- | --- | --- | --- |
| Total revenues | $1,458,086 | 17% vs Q3 2025 | GAAP |
| Net income | $2,167,335 | vs $292,683 in Q3 2025 | GAAP |
| Diluted EPS | $15.72 | vs $2.14 in Q3 2025 | GAAP |
| Non-GAAP diluted EPS | $16.26 | up 410% from a year ago | non-GAAP |
| GAAP income from operations | $345,798 | down 6% from a year ago | GAAP |
| Total net product revenues | $1,292 Million | 52% growth compared with Q3 2025 |  |

## Segments and operating metrics

| Name | Value | Change |
| --- | --- | --- |
| AMVUTTRA net product revenues | $1,130,363 | 65% vs Q3 2025 |
| ONPATTRO net product revenues | 19,596 | (50)% vs Q3 2025 |
| GIVLAARI net product revenues | 89,487 | 21% vs Q3 2025 |
| OXLUMO net product revenues | 52,500 | (1)% vs Q3 2025 |
| Royalty revenue | 94,664 | 105% vs Q3 2025 |

## Outlook

| Metric | Period | Outlook |
| --- | --- | --- |
| Total TTR net product revenues | FY 2026 | $4,200 million - $4,500 million |
| Total Rare net product revenues | FY 2026 | $500 million - $600 million |
| Total net product revenues | FY 2026 | $4,700 million - $5,100 million |
| Net revenues from collaborations and royalties | FY 2026 | $575 million - $625 million |
| Non-GAAP R&D and SG&A expenses | FY 2026 | $2,700 million - $2,800 million |

## Key takeaways

1. **TRITON-CM enrollment expanded without delaying launch** Alnylam is raising target enrollment from 1,750 to approximately 2,250 patients, enriched for early disease and sized for conservative event rates. It still expects a nucresiran ATTR-CM launch by 2030, so the larger trial is meant to improve the chance of success.
2. **AMVUTTRA prescriber base keeps broadening** U.S. ATTR-CM category prescriptions grew about 70% year over year, and more than 2,000 new unique AMVUTTRA prescribers have been added since March 2025. Alnylam says about 80% of ATTR-CM patients remain untreated, so the growth is still early.
3. **HELIOS-B data back first-line positioning** A subgroup analysis showed consistent benefit with or without baseline tafamidis use, and further analyses covered multisystemic manifestations and sex. This supports the case for vutrisiran as a first-line ATTR-CM treatment against competing therapies.
4. **Brezosiran opens a path beyond TTR** Phase 1 data showed a 60-64% mean CSF mHTT reduction at month 3 in the highest dose group, with an encouraging safety profile. A placebo-controlled pivotal study is planned for 2027, pending regulatory alignment, in collaboration with Regeneron.
5. **340B reimbursement change is a access risk** A proposed CMS rule would cut hospital outpatient reimbursement for Part B medicines bought under 340B, effective January 1, 2027 if implemented. Alnylam plans to respond through health system contracting and alternative sites of care such as home care and third-party infusion clinics.

## Questions

**What changed for the TRITON-CM nucresiran trial?** Target enrollment rose from 1,750 to approximately 2,250 patients, enriched for early disease to ensure adequate power. Alnylam still expects an ATTR-CM launch by 2030, assuming positive data and approval.
**How is AMVUTTRA demand developing in the U.S.?** ATTR-CM category prescriptions grew about 70% year over year, and AMVUTTRA reached a 37% total prescription share in ATTR. More than 2,000 new unique prescribers have been added since March 2025.
**What did Alnylam report for brezosiran in Huntington's disease?** Phase 1 patients showed a 60-64% mean CSF mHTT reduction at month 3 in the highest dose group, with a good safety profile so far. A placebo-controlled pivotal study is planned for 2027, pending regulatory alignment.
**What is the risk from 340B changes?** A proposed CMS rule would reduce hospital outpatient reimbursement for Part B medicines acquired through 340B, effective January 1, 2027 if implemented. Alnylam points to health system contracting and alternative care sites to mitigate patient access risk.
**Is Alnylam changing its 2026 guidance?** No. It reiterated full-year 2026 total net product revenue guidance of $4,700 million - $5,100 million and said it is on track to achieve its 2026 financial guidance.

## Slides and investor documents

- [alnylam-q3-2026-earnings-presentation.pdf](https://investors.alnylam.com/sites/default/files/pdfs/alnylam-q3-2026-earnings-presentation.pdf) (Slide deck)

